Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
May 26, 2022 17:00 ET
|
Galera Therapeutics
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy Company on...
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
May 16, 2022 07:30 ET
|
Galera Therapeutics
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of...
Galera Announces Plan to Submit Avasopasem NDA by Year End
May 16, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
May 02, 2022 07:00 ET
|
Galera Therapeutics
Incidence of Grade 3 esophagitis substantially reduced in patients treated with avasopasem compared to literature No Grade 4 or 5 esophagitis in patients treated with avasopasem MALVERN, Pa, May...
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 ET
|
Galera Therapeutics
MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
March 10, 2022 07:00 ET
|
Galera Therapeutics
Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission Data readouts from AESOP in...
Galera to Present at H.C. Wainwright BioConnect Conference
January 06, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
December 14, 2021 07:00 ET
|
Galera Therapeutics
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045)Topline results...
Galera to Present at Two Upcoming Investor Conferences in November
November 15, 2021 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
November 10, 2021 07:00 ET
|
Galera Therapeutics
Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in...